Pfizer Inc. (NYSE:PFE) Shares Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp grew its position in Pfizer Inc. (NYSE:PFE) by 8.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 241,680 shares of the biopharmaceutical company’s stock after acquiring an additional 18,448 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Pfizer were worth $6,412,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PFE. Norges Bank acquired a new stake in Pfizer during the fourth quarter worth approximately $2,328,986,000. Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Pfizer in the fourth quarter valued at $274,694,000. Massachusetts Financial Services Co. MA lifted its position in Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares during the last quarter. Finally, APG Asset Management N.V. lifted its position in Pfizer by 1,106.0% in the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock valued at $143,967,000 after acquiring an additional 5,153,257 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 1.0%

NYSE:PFE opened at $22.86 on Wednesday. The stock has a fifty day moving average price of $23.89 and a two-hundred day moving average price of $25.46. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $129.97 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period last year, the company posted $0.82 earnings per share. The firm’s quarterly revenue was down 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.52%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research reports. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.